Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | DHFR | P00374 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524062 | 0.87 | PTPN1 (0.55) | PTPN1DHFRCYP2C9CYP2D6CYP3A4 | |
| SCHEMBL4526032 | 0.81 | KCNH2 (0.44) | PTPN1TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL4559995 | 0.80 | ALOX5AP (0.40) | PTPN1DHFRNLRP3 | |
| SCHEMBL4513782 | 0.79 | PTPN1 (0.66) | PTPN1TLR8TLR7DHFRCYP2C9 | |
| SCHEMBL4514410 | 0.77 | KCNH2 (0.40) | TLR7DHFRKCNH2NLRP3 | |
| SCHEMBL4529385 | 0.77 | PTPN1 (0.54) | PTPN1DHFR | |
| SCHEMBL4517419 | 0.77 | PTPN1 (0.54) | PTPN1DHFR | |
| Trifluoroacetic Acid SCHEMBL4528727 | 0.76 | KCNH2 (0.38) | PTPN1TLR8TLR7CYP2C9KCNH2 | |
| SCHEMBL4515282 | 0.76 | TLR8 (0.38) | TLR8TLR7CYP2C9KCNH2NLRP3 | |
| SCHEMBL4525906 | 0.75 | SLC6A3 (0.53) | PTPN1TLR8TLR7DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885TLR8 3037/4885TLR7 2015/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885TLR8 3037/4885TLR7 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.